Preoperative plasma aldosterone and the risk of atrial fibrillation after coronary artery bypass surgery

Alexandre, Jonas; Saloux, Éric; Chequel, Mathieu; Allouche, Stéphane; Ollitrault, Pierre; Plane, Anne-Flore; Legallois, Damien; Fischer, Marc-Olivier; Saplacan, Vladimir; Buklas, Dimitrios; Labombarda, Fabien; Blanchart, Katrien; Salem, Joe‐Elie; Nowoczyn, Marie; Puddu, Paolo Emilio; Manrique, Alain; Parienti, Jean‐Jacques; Milliez, Paul

doi:10.1097/hjh.0000000000001105

Cited by 26 publications

(13 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the 38 full‐text articles assessed for eligibility, ten were excluded for the following reasons: One study lacked a control group; one study population was heart failure; four studies lacked available data for further analysis; and four reported duplicate data from studies that later published as full text . Finally, 28 studies involving 10 830 patients were included in our meta‐analysis, with their baseline characteristics shown in Tables and .…”

Section: Resultsmentioning

confidence: 99%

Galectin‐3 and risk of atrial fibrillation: A systematic review and meta‐analysis

Gong

Cheung

Wang

et al. 2020

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background Galectin‐3 is an inflammatory marker that is raised in myocardial fibrosis and inflammation. Recent studies have explored its role in predicting atrial fibrillation (AF) outcomes. The aim of this systematic review and meta‐analysis is to examine the association between serum concentration of galectin‐3 and AF. Methods PubMed, EMBASE, and the Cochrane Database were searched. A total of 280 studies were identified, of which 28 studies involving 10 830 patients were included in our meta‐analysis. Results Galectin‐3 is present at higher concentrations in patients with AF than those in sinus rhythm (mean difference [MD] = −0.68 ng/mL, 95% CI: −0.92, −0.44, Z = 5.61, P < .00001). Galectin‐3 levels were significantly higher in the persistent AF than in the paroxysmal AF group (MD = −0.94 ng/mL, 95% CI: −1.85, −0.03, Z = 2.04, P = .04). Higher galectin‐3 levels were associated with a 45% increase in the odds of developing AF (odds ratio [OR] = 1.45, 95% CI: 1.15, 1.83, Z = 3.11, P = .002) and risk of AF recurrence (hazard ratio [HR] =1.17, 95% CI: 1.06, 1.29, Z = 3.12, P = .002). Conclusions Our meta‐analysis found that galectin‐3 is significantly higher in patients with persistent AF than in those with paroxysmal AF, and can predict both AF development and recurrence after treatment.

show abstract

Section: Resultsmentioning

confidence: 99%

Galectin‐3 and risk of atrial fibrillation: A systematic review and meta‐analysis

Gong

Cheung

Wang

et al. 2020

Clinical Laboratory Analysis

View full text Add to dashboard Cite

show abstract

“…Several risk factors, 27,28 biomarkers, 29,30 and genetic variants 31,32 have been investigated and linked to POAF but have not proven to be particularly sensitive in predicting which patients will develop POAF. Risk indexes that attempt to predict an individual's risk for developing POAF have been developed, 29,[33][34][35][36] but these too suffer from lack of specificity predicting which patients will develop POAF.…”

Section: Introductionmentioning

confidence: 99%

Clinical Risk Factors for Postoperative Atrial Fibrillation among Patients after Cardiac Surgery

Yamashita

Ranjan

et al. 2018

Thorac cardiovasc Surg

View full text Add to dashboard Cite

show abstract

“…Finally, the LA myocardium extends beyond the atriovenous junction and over the PVs (myocardial sleeves) and PAR1 expression is not expected to be different between LA and RA based on previous reports . Total RNAs were extracted using the TRIzol reagent (Promega, Madison, Washington, USA) according to previous reported protocol . cDNAs were synthesized from 3 μg of RNA in a buffer supplied with the reverse transcriptase (Promega) containing 900 μ m dNTP (Amersham Pharmacia Biotech, Buckinghamshire, UK), 20U RNAsine (Promega), 500 ng random primers (Promega), and 200U of Moloney murine leukemia virus reverse transcriptase in a final volume of 20 μL.…”

Section: Methodsmentioning

confidence: 99%

PAR1 contribution in acute electrophysiological properties of oral anticoagulants in rabbit pulmonary vein sleeve preparations

Font

Simeon

Simard

et al. 2018

Fundamemntal Clinical Pharma

Self Cite

View full text Add to dashboard Cite

Whether oral anticoagulants, vitamin K antagonists (VKAs), and nonvitamin K oral anticoagulant (NOACs) frequently prescribed to atrial fibrillation (AF) patients, do themselves have a pro- or anti-arrhythmic effect have never been addressed. Transmembrane action potentials were recorded in an acute rabbit model of superfused pulmonary veins (PVs) sleeves preparations using standard microelectrode technique. Fluindione 10 μm (n = 6) increased the AP (action potential) duration (APD), induced a significantly V depression (from 95 ± 14 to 53 ± 5 V/s, P < 0.05), and 2 : 1 blocks during rapid atrial pacing thus evoking class I anti-arrhythmic properties, and prevented spontaneous trigger APs. Apixaban 10 μm (n = 6) increased the APD, significantly prolonged the effective refractory period (from 56.3 ± 4.2 to 72.0 ± 8.6 ms, P < 0.05), and prevented triggered APs occurrence. Fluindione and apixaban effects were suppressed with the addition of the protease-activated receptors 1 (PAR 1) agonist SFLLR-NH . Warfarin 10 μm (n = 6) significantly abbreviated the early refractory period (from 56.3 ± 4.2 to 45.0 ± 2.2 ms, P < 0.05) and increased triggered APs occurrence that were successfully prevented by nifedipine but not by the addition of the protease-activated receptors 1 agonist SFLLR-NH . In this acute rabbit PVs model, VKAs and NOACs, at physiological concentrations, exhibited very different pharmacological properties that influence PVs electrophysiology, implying PAR1, with fluindione and apixaban which exhibited more anti-arrhythmic properties, whereas warfarin exhibited more pro-arrhythmic properties.

show abstract

Preoperative plasma aldosterone and the risk of atrial fibrillation after coronary artery bypass surgery

Abstract: We developed the preoperative 'Aldoscore' for POAF risk stratification among patients with preserved LVEF requiring elective CABG. This new tool may be helpful to identify good responders to interventions targeting the proarrhythmic and profibrotic pathways of aldosterone.

Cited by 26 publications

References 32 publications

Galectin‐3 and risk of atrial fibrillation: A systematic review and meta‐analysis

Galectin‐3 and risk of atrial fibrillation: A systematic review and meta‐analysis

Clinical Risk Factors for Postoperative Atrial Fibrillation among Patients after Cardiac Surgery

PAR1 contribution in acute electrophysiological properties of oral anticoagulants in rabbit pulmonary vein sleeve preparations

Contact Info

Product

Resources

About